Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08-Reference-Cited by-同舟云学术

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

Published:2006-08-15 Issue:16 Volume:12 Page:4899-4907
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Wen Patrick Y.,Yung W.K. Alfred,Lamborn Kathleen R.,Dahia Patricia L.,Wang Yanfeng,Peng Bin,Abrey Lauren E.,Raizer Jeffrey,Cloughesy Timothy F.,Fink Karen,Gilbert Mark,Chang Susan,Junck Larry,Schiff David,Lieberman Frank,Fine Howard A.,Mehta Minesh,Robins H. Ian,DeAngelis Lisa M.,Groves Morris D.,Puduvalli Vinay K.,Levin Victor,Conrad Charles,Maher Elizabeth A.,Aldape Kenneth,Hayes Michael,Letvak Laurie,Egorin Merrill J.,Capdeville Renaud,Kaplan Richard,Murgo Anthony J.,Stiles Charles,Prados Michael D.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 370 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma;Scientific Reports;2024-09-02

2. CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma lines;2024-06-30

3. Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma;Brain Communications;2024

4. Druggable genomic landscapes of high-grade gliomas;Frontiers in Medicine;2023-12-08

5. From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress;Signal Transduction and Targeted Therapy;2023-10-20